By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Otonomy, Inc. 

6275 Nancy Ridge Drive
Suite 100
San Diego  California  92121  U.S.A.
Phone: 858-242-5200 Fax: 858-200-0933


Otonomy is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics to address diseases of the inner and middle ear. There are no drugs currently approved by the FDA for the lead indications we are currently pursuing for our product candidates. Our lead candidate AuriPro completed Phase 3 clinical trials in pediatric patients with middle ear effusion at the time of tympanostomy tube placement surgery, and we have submitted a request to the FDA for approval. If approved, we anticipate a commercial launch in early 2016 and are building our business and commercial team to meet the needs of this next stage of our growth.

Key Statistics

Ownership: Public

Web Site: Otonomy
Symbol: OTIC


Company News
Otonomy (OTIC) Holds Investor And Analyst Day And Provides Corporate Update 10/7/2015 8:12:15 AM
Otonomy (OTIC) Receives FDA Clearance of Investigational New Drug Application for Tinnitus Product Candidate, OTO-311 10/5/2015 5:59:54 AM
Otonomy (OTIC) To Host Investor And Analyst Day On October 7, 2015 9/30/2015 8:35:03 AM
Otonomy (OTIC)To Present Results For Auripro Phase III And OTO-104 Phase IIb Clinical Trials At 2015 AAO-HNSF Annual Meeting 9/24/2015 8:00:56 AM
Otonomy (OTIC) Announces Successful End-Of-Phase II Meeting With The FDA For OTO-104 In Meniere's Disease 9/9/2015 7:21:28 AM
Otonomy (OTIC) Reports Second Quarter 2015 Financial Results And Provides Corporate Update 8/13/2015 12:00:25 PM
Otonomy (OTIC) Initiates Phase II Clinical Trial For Auripro In Second Label Expansion Indication 7/28/2015 6:59:19 AM
Otonomy (OTIC) Reports Phase IIb Topline Data for OTO-104 in Meniere's Disease 5/22/2015 7:47:38 AM
Otonomy (OTIC) Plunges After Near-Miss Stage IIb Trial for Ear Drug 5/21/2015 4:37:02 PM
Otonomy, Inc. (OTIC) Appoints Eric Loumeau As General Counsel And Chief Compliance Officer 5/18/2015 7:51:44 AM